Oligonucleotide synthesis is complex, and the process comes with limitations, particularly with respect to scalability. There are challenges inherent to translating the chemistry and processes developed on benchtop synthesizers to larger-scale pilot or production platforms, no matter which manufacturer you use at a small scale. Even scale-up on the same manufacturer’s equipment is not always a straightforward one-for-one transition, contrary to common belief. To get the full story, download the article from Asahi Kasei Bioprocess and Downstream Column.
